Global, Regional, and National Burden of Hematologic Malignancies From 1990 to 2021, With Projections of Mortality and Incidence to 2031.
1/5 보강
[BACKGROUND] Global analyses of hematologic malignancies often lack subtype integration and advanced forecasting, limiting public health planning.
- p-value p < 0.001
APA
Kou Y, Chen F, et al. (2026). Global, Regional, and National Burden of Hematologic Malignancies From 1990 to 2021, With Projections of Mortality and Incidence to 2031.. Psycho-oncology, 35(1), e70365. https://doi.org/10.1002/pon.70365
MLA
Kou Y, et al.. "Global, Regional, and National Burden of Hematologic Malignancies From 1990 to 2021, With Projections of Mortality and Incidence to 2031.." Psycho-oncology, vol. 35, no. 1, 2026, pp. e70365.
PMID
41506717
Abstract
[BACKGROUND] Global analyses of hematologic malignancies often lack subtype integration and advanced forecasting, limiting public health planning.
[METHODS] Using GBD 2021 data (1990-2021), we analyzed age-standardized incidence (ASIR), mortality (ASDR), and disability-adjusted life years (DALYs) for leukemia, lymphoma, and multiple myeloma. Spatiotemporal models quantified age-, sex-, and Socio-demographic Index (SDI)-stratified disparities. The Prophet model forecasted trends to 2031.
[RESULTS] In 2021, global ASIRs were 5.63, 7.93, and 1.74 per 100,000 for leukemia, lymphoma, and multiple myeloma, respectively. ASIR correlated positively with SDI for all subtypes (e.g., multiple myeloma: ρ = 0.81, p < 0.001). Mortality patterns were heterogeneous; Hodgkin lymphoma ASDR correlated negatively with SDI (ρ = -0.26, p < 0.001). Projections suggest stable or declining ASDRs by 2031 (e.g., leukemia: 3.86 to 3.40) but persistent male predominance. DALYs remain high in low-SDI regions.
[DISCUSSION] The disparity between high incidence in high-SDI areas and higher mortality fractions in low-SDI areas underscores diagnostic and therapeutic inequities. DALYs reflect associated long-term functional and psychosocial burden.
[CONCLUSION] This study reveals profound global inequalities in hematologic malignancies. Mitigating this burden requires strengthening early diagnosis and treatment in low-SDI regions while integrating psychosocial support into global survivorship care.
[METHODS] Using GBD 2021 data (1990-2021), we analyzed age-standardized incidence (ASIR), mortality (ASDR), and disability-adjusted life years (DALYs) for leukemia, lymphoma, and multiple myeloma. Spatiotemporal models quantified age-, sex-, and Socio-demographic Index (SDI)-stratified disparities. The Prophet model forecasted trends to 2031.
[RESULTS] In 2021, global ASIRs were 5.63, 7.93, and 1.74 per 100,000 for leukemia, lymphoma, and multiple myeloma, respectively. ASIR correlated positively with SDI for all subtypes (e.g., multiple myeloma: ρ = 0.81, p < 0.001). Mortality patterns were heterogeneous; Hodgkin lymphoma ASDR correlated negatively with SDI (ρ = -0.26, p < 0.001). Projections suggest stable or declining ASDRs by 2031 (e.g., leukemia: 3.86 to 3.40) but persistent male predominance. DALYs remain high in low-SDI regions.
[DISCUSSION] The disparity between high incidence in high-SDI areas and higher mortality fractions in low-SDI areas underscores diagnostic and therapeutic inequities. DALYs reflect associated long-term functional and psychosocial burden.
[CONCLUSION] This study reveals profound global inequalities in hematologic malignancies. Mitigating this burden requires strengthening early diagnosis and treatment in low-SDI regions while integrating psychosocial support into global survivorship care.
MeSH Terms
Humans; Male; Female; Incidence; Hematologic Neoplasms; Middle Aged; Adult; Aged; Disability-Adjusted Life Years; Global Health; Global Burden of Disease; Multiple Myeloma; Adolescent; Leukemia; Lymphoma; Young Adult; Mortality; Aged, 80 and over; Child; Infant; Child, Preschool
같은 제1저자의 인용 많은 논문 (3)
- Prognostic value and predictive biomarkers of synergistic interaction between tumor-associated macrophages and cancer stem cells in colorectal cancer.
- Dioscin suppresses epithelial-mesenchymal transition in gastric cancer by upregulating Cx43 to inhibit the VEGFA/PI3K/Akt/mTOR pathway.
- Global, regional, and Chinese disease burden and trends of colorectal cancer, 1990-2021: An update from the GBD 2021 study and implications for predictive, preventive, and personalized medicine.